Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
TOKYO and CAMBRIDGE, Mass., Jan 10, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia…
Read More
0
